Invivyd (NASDAQ:IVVD) Announces Quarterly Earnings Results

Invivyd (NASDAQ:IVVD) announced its earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10, Zacks reports. The firm had revenue of $13.80 million for the quarter, compared to the consensus estimate of $13.57 million.

Invivyd Price Performance

Shares of IVVD opened at $0.74 on Friday. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74. The firm has a market cap of $88.28 million, a PE ratio of -0.38 and a beta of 0.09. The stock’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $0.87.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the transaction, the director now directly owns 3,170,231 shares in the company, valued at $1,521,710.88. This trade represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 246,138 shares of company stock worth $120,902. 17.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IVVD shares. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research report on Monday, February 24th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.